Work

Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes

Year: 2018

Type: article

Study design: Clinical Trial

Abstract: = .03). All adverse events were self-limited, and none led to drug discontinuation. Affected tissue biopsy samples in 2 subjects showed normalization of pathology and depletion of eosinophils on dexpramipexole. Bone marrow biopsy samples after 12 weeks of dexpramipexole showed selective absence of mature eosinophils in responders. Dexpramipexole appears promising as a GC-sparing agent without apparent toxicity in a subset of subjects with GC-responsive HESs. Although the exact mechanism of action is unknown, preliminary data suggest that dexpramipexole may affect eosinophil maturation in the bone marrow. This study was registered at www.clinicaltrials.gov as #NCT02101138.

Source: Blood

DOI: 10.1182/blood-2018-02-835330

Authors: Sandhya R. Panch, Michael E. Bozik, Thomas Brown, Michelle Makiya, Calman Prussin, Donald G. Archibald, Gregory T. Hebrank, Mary Sullivan, Xiaoping Sun, Lauren Wetzler, JeanAnne Ware, Michael P. Fay, Cynthia E. Dunbar, Steven I. Dworetzky, Paneez Khoury, Irina Maric, Amy D. Klion

Institutions: National Institutes of Health, National Institutes of Health Clinical Center, Knopp Biosciences (United States), National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute

Language: English

Topic: Eosinophilic Disorders and Syndromes

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, NIH Clinical Center, NHLBI Division of Intramural Research

OpenAlex ID: W2800623957

FWCI: 4.778

Cites: 23

Cited by: 63

Related to: 10